Promote HIV Chemoprophylaxis Research, Don't Prevent It
- 30 September 2005
- journal article
- policy forum
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 309 (5744), 2170-2171
- https://doi.org/10.1126/science.1116204
Abstract
Preexposure chemoprophylaxis (PrEP) is a promising approach to HIV-1 prevention that warrants clinical evaluation, especially in regions of the world hit hardest by the epidemic. Controversy has arisen that highlights the needs of high-risk populations who frequently have limited access to information and medical care. The authors of this Policy Forum recommend involvement of community leaders and local investigators early in the development of research projects, open communication of accurate information about research, and active development of prevention and treatment infrastructure, which all serve to build the community trust that is the basis for research into finding ways to stop the spread of HIV/AIDS.Keywords
This publication has 11 references indexed in Scilit:
- Media reporting of tenofovir trials in Cambodia and CameroonBMC International Health and Human Rights, 2005
- The Abandoned Trials of Pre-Exposure Prophylaxis for HIV: What Went Wrong?PLoS Medicine, 2005
- HIV Sexual Risk Behavior Over 36 Months of Follow-Up in the World's First HIV Vaccine Efficacy TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled studyThe Lancet, 2004
- Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?AIDS, 2003
- Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase InhibitorsAntimicrobial Agents and Chemotherapy, 2002
- Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected AdultsAntimicrobial Agents and Chemotherapy, 2001
- Two Low Doses of Tenofovir Protect Newborn Macaques against Oral Simian Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2001
- Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenineScience, 1995